Prevalence of risk factors in men with premature coronary artery disease

The American Journal of Cardiology

Volumn 67, Issue 15, 1991, Pages 1185-1189

  Genest, Jacques J ^a,b   McNamara, Judith R ^a,b   Salem, Deeb N ^a,b   Schaefer, Ernst J ^a,b  

^a TUFTS UNIVERSITY   (United States)

^b TUFTS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; LIPOPROTEIN;

ADULT; ARTICLE; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK FACTOR;

ADULT; COMPARATIVE STUDY; CORONARY DISEASE; DIABETES MELLITUS; HUMAN; HYPERTENSION; LIPOPROTEINS, HDL CHOLESTEROL; LIPOPROTEINS, LDL CHOLESTEROL; MALE; MASSACHUSETTS; MIDDLE AGE; PREVALENCE; RISK FACTORS; SMOKING; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, NON-P.H.S.; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0025731272     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/0002-9149(91)90924-A     Document Type: Article

References (30)

1. The Framingham Study. Lipids and atherosclerotic disease
2. Is the relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT)
3. Serum cholesterol, blood pressure, and mortality: implications from a cohort of 361,662 men
4. Clofibrate and niacin in coronary heart disease
5. The Lipid Research Clinics Coronary Primary Prevention Trial Results I Reduction in incidence of coronary heart disease
6. The Lipid Research Clinics Coronary Primary Prevention Trial Results II The relationship of reduction in incidence of coronary heart disease to cholesterol lowering
7. Helsinki Heart Study: primary prevention trial with gemfibrozil in middle-aged men with dyslipidemia
8. Report of the National Cholesterol Education Program Expert Panel on detection evaluation and treatment of high blood cholesterol in adults
9. Canadian Consensus Conference on Cholesterol: Final Report
10. Strategies for the prevention of coronary heart disease: a policy statement of the European Atherosclerosis Society
11. Fifteen-year mortality in coronary drug project patients: longterm benefit with niacin
12. Reduction of mortality in the Stockholm ischaemic heart disease secondary prevention study by combined treatment with clofibrate and nicotinic acid
13. Fibric acids effect on lipids and lipoprotein metabolism
14. HMG-CoA reductase inhibitors for treatment of hypercholesterolemia
15. The prevalence of high blood cholesterol levels among adults in the United States
16. Impact of national guidelines for cholesterol risk factor screening. The Framingham Offspring Study
17. High-density lipoproteins-the clinical implications of recent studies
18. Automated enzymatic standardized lipid analyses for plasma and lipoprotein fractions
19. 2+ precipitation procedure for quantitation of high-density lipoprotein cholesterol
20. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge
21. Effect of hospitalization on high-density lipoprotein cholesterol in patients undergoing elective coronary angiography
22. Effect of hospitalization on plasma lipoprotein cholesterol and apolipoproteins A–I, B and Lp(a)
23. Validation of a semi-quantitative food-frequency questionnaire comparison with a 1 year diet
24. Quantitative effect of dietary fat on serum cholesterol in man
25. The effect of beta-adrenergic blocking agents on blood lipid levels
26. Multiple Risk Factor Intervention Trial risk factor changes and mortality results
27. Beta-adrenergic blockade for survivors of acute myocardial infarction
28. High density lipoprotein cholesterol, total cholesterol screening, and myocardial infarction. The Framingham Study
29. Dyslipidemias with desirable plasma total cholesterol levels and angiographically demonstrated coronary artery disease
30. Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study